TCRX TSC-101 reports 79% 6-month relapse-free survival in post-HCT
TSC-101 in high-risk post-HCT patients showed 79% relapse-free survival at 6 months, with safety also reported in the heme program.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.